{"commentary":{"count":26,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":15,"youtube":7,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03809988\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PALMIRA","nct_id":"NCT03809988","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=palmira-nct03809988. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PALMIRA","arms":[{"description":"Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).","label":"Interventional Arm (Arm A)","type":"EXPERIMENTAL"},{"description":"Patients will receive endocrine therapy (letrozole or fulvestrant).","label":"Control Arm (Arm B)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Pfizer"],"completion_date":{"date":"2022-11-30","type":"ACTUAL"},"conditions":["Breast Cancer","Advanced Breast Cancer","Hormone Receptor Positive Tumor","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast"],"enrollment":{"count":198,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Palbociclib","type":"DRUG"},{"name":"Endocrine therapy","type":"DRUG"}],"last_update":"2023-09-07","lead_sponsor":"MedSIR","official_title":"International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-11-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS (Progression-free survival)","timeFrame":"Baseline up to 29 months"}],"references":[{"citation":"Llombart-Cussac A, Harper-Wynne C, Perello A, Hennequin A, Fernandez-Ortega A, Colleoni M, Marin S, Quiroga V, Medioni J, Iranzo V, Wheatley D, Del Barco Berron S, Anton A, Dobi E, Ruiz-Borrego M, Alcala-Lopez D, Perez-Escuredo J, Antonarelli G, Sampayo-Cordero M, Perez-Garcia JM, Cortes J. Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial. J Clin Oncol. 2025 Jun 20;43(18):2084-2093. doi: 10.1200/JCO-24-01865. Epub 2025 Apr 28.","pmid":"40294349","type":"DERIVED"}],"start_date":{"date":"2019-04-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)","url":"https://clinicaltrials.gov/study/NCT03809988"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/palmira-nct03809988"}